The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Total white blood cell count (TWBCc), an index of chronic and low-grade inflammation, is associated with clinical symptoms and metabolic alterations in patients with schizophrenia. The effect of antipsychotics on TWBCc, predictive values of TWBCc for drug response, and role of metabolic alterations require further study.
METHODS: Patients with schizophrenia were randomized to monotherapy with risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, perphenazine or haloperidol in a 6-week pharmacological trial. We repeatedly measured clinical symptoms, TWBCc, and metabolic measures (body mass index, blood pressure, waist circumference, fasting blood lipids and glucose). We used mixed-effect linear regression models to test whether TWBCc can predict drug response. Mediation analysis to investigate metabolic alteration effects on drug response.
RESULTS: At baseline, TWBCc was higher among patients previously medicated. After treatment with risperidone, olanzapine, quetiapine, perphenazine, and haloperidol, TWBCc decreased significantly (p < 0.05). Lower baseline TWBCc predicted greater reductions in Positive and Negative Syndrome Scale (PANSS) total and negative scores over time (p < 0.05). We found significant mediation of TWBCc for effects of waist circumference, fasting low-density lipoprotein cholesterol, and glucose on reductions in PANSS total scores and PANSS negative subscale scores (p < 0.05).
CONCLUSION: TWBCc is affected by certain antipsychotics among patients with schizophrenia, with decreases observed following short-term, but increases following long-term treatment. TWBCc is predictive of drug response, with lower TWBCc predicting better responses to antipsychotics. It also mediates the effects of certain metabolic measures on improvement of negative symptoms. This indicates that the metabolic state may affect clinical manifestations through inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current neuropharmacology - 22(2023), 1 vom: 04., Seite 159-167 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yamin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.11.2023 Date Revised 15.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1570159X21666230104090046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351117954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351117954 | ||
| 003 | DE-627 | ||
| 005 | 20231227131049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1570159X21666230104090046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM351117954 | ||
| 035 | |a (NLM)36600620 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yamin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2023 | ||
| 500 | |a Date Revised 15.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Total white blood cell count (TWBCc), an index of chronic and low-grade inflammation, is associated with clinical symptoms and metabolic alterations in patients with schizophrenia. The effect of antipsychotics on TWBCc, predictive values of TWBCc for drug response, and role of metabolic alterations require further study | ||
| 520 | |a METHODS: Patients with schizophrenia were randomized to monotherapy with risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, perphenazine or haloperidol in a 6-week pharmacological trial. We repeatedly measured clinical symptoms, TWBCc, and metabolic measures (body mass index, blood pressure, waist circumference, fasting blood lipids and glucose). We used mixed-effect linear regression models to test whether TWBCc can predict drug response. Mediation analysis to investigate metabolic alteration effects on drug response | ||
| 520 | |a RESULTS: At baseline, TWBCc was higher among patients previously medicated. After treatment with risperidone, olanzapine, quetiapine, perphenazine, and haloperidol, TWBCc decreased significantly (p < 0.05). Lower baseline TWBCc predicted greater reductions in Positive and Negative Syndrome Scale (PANSS) total and negative scores over time (p < 0.05). We found significant mediation of TWBCc for effects of waist circumference, fasting low-density lipoprotein cholesterol, and glucose on reductions in PANSS total scores and PANSS negative subscale scores (p < 0.05) | ||
| 520 | |a CONCLUSION: TWBCc is affected by certain antipsychotics among patients with schizophrenia, with decreases observed following short-term, but increases following long-term treatment. TWBCc is predictive of drug response, with lower TWBCc predicting better responses to antipsychotics. It also mediates the effects of certain metabolic measures on improvement of negative symptoms. This indicates that the metabolic state may affect clinical manifestations through inflammation | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Schizophrenia | |
| 650 | 4 | |a antipsychotics | |
| 650 | 4 | |a drug response | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a metabolic alterations. | |
| 650 | 4 | |a white blood cell | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Olanzapine |2 NLM | |
| 650 | 7 | |a N7U69T4SZR |2 NLM | |
| 650 | 7 | |a Risperidone |2 NLM | |
| 650 | 7 | |a L6UH7ZF8HC |2 NLM | |
| 650 | 7 | |a Quetiapine Fumarate |2 NLM | |
| 650 | 7 | |a 2S3PL1B6UJ |2 NLM | |
| 650 | 7 | |a Haloperidol |2 NLM | |
| 650 | 7 | |a J6292F8L3D |2 NLM | |
| 650 | 7 | |a Perphenazine |2 NLM | |
| 650 | 7 | |a FTA7XXY4EZ |2 NLM | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Tao, Shiwan |e verfasserin |4 aut | |
| 700 | 1 | |a Coid, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yue, Weihua |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Liwen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Guigang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Tianlan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lifang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fuquan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianli |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Keqing |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Luxian |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Qingrong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Fude |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lingjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chuanyue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Liansheng |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Wanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current neuropharmacology |d 2004 |g 22(2023), 1 vom: 04., Seite 159-167 |w (DE-627)NLM175794456 |x 1875-6190 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:04 |g pages:159-167 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1570159X21666230104090046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 1 |b 04 |h 159-167 | ||